Dr. Carey Anders on Treating Brain Metastases in Breast Cancer

Publication
Video
Special ReportsBreast Cancer (Issue 2)
Volume 1
Issue 2

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, on the challenge of treating brain metastases in breast cancer. Anders says brain metastases generally portend a poor prognosis and treatment for them are currently scarce.

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, on the challenge of treating brain metastases in breast cancer. Anders says brain metastases generally portend a poor prognosis and treatment for them are currently scarce.

Articles in this issue
Glembatumumab and the Phase IIb Registrational METRIC Trial: Q&A With Denise Yardley, MD, and Linda Vahdat, MD
Glembatumumab and the Phase IIb Registrational METRIC Trial: Q&A With Denise Yardley, MD, and Linda Vahdat, MD
Survival Improved Over 10 Years With Breast-Conserving Therapy Versus Mastectomy
Survival Improved Over 10 Years With Breast-Conserving Therapy Versus Mastectomy
Dr. Carey Anders on Treating Brain Metastases in Breast Cancer
Dr. Carey Anders on Treating Brain Metastases in Breast Cancer
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment
Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Cancer
Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Cancer
Avelumab Shows Efficacy in PD-L1-Positive Metastatic Breast Cancer
Avelumab Shows Efficacy in PD-L1-Positive Metastatic Breast Cancer
The Complications and Costs in Mastectomies and Lumpectomies in Early Breast Cancer
The Complications and Costs in Mastectomies and Lumpectomies in Early Breast Cancer
Study Links pCR Post-Neoadjuvant Therapy to Increased Survival Rates in TNBC
Study Links pCR Post-Neoadjuvant Therapy to Increased Survival Rates in TNBC
Recent Videos
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Related Content
ctDNA Monitoring in Breast Cancer Treatment: Early Signs and Future Directions

ctDNA Monitoring in Breast Cancer Treatment: Early Signs and Future Directions

Sabrina Serani
July 26th 2024
Article

Mridula George, MD, discussed a study investigating ctDNA monitoring during neoadjuvant therapy of breast cancer.

Read More

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022
Podcast

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Listen

Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy

Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy

Targeted Oncology Staff
July 24th 2024
Article

During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.

Read More

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

Nichole Tucker
September 25th 2020
Podcast

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Listen

Double Trouble for Breast Cancer: Are Two ADCs Better Than One?

Double Trouble for Breast Cancer: Are Two ADCs Better Than One?

Sabrina Serani
July 23rd 2024
Article

Laura Huppert, MD, discussed a retrospective study exploring the sequential use of antibody-drug conjugates for the treatment of HER2-low metastatic breast cancer.

Read More

Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer

Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer

Targeted Oncology Staff
July 23rd 2024
Article

In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.

Read More